Updated guidelines for managing fungal diseases in hematology patients

References

• Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med.356, 348–359 (2007).
   PubMed Web of Science ®Google Scholar
• Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med.326, 845–851 (1992).
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med.347, 408–415 (2002).
   PubMed Web of Science ®Google Scholar
• Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomized double blind study. J. Infect. Dis.171, 1545–1552 (1995).
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis.34, 7–14 (2002).
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh T, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group. Clin. Infect. Dis.46, 1813–1821 (2008).
   PubMed Web of Science ®Google Scholar
• Segal BH, Herbrecht R, Stevens DA et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin. Infect. Dis.47, 674–683 (2008).
   PubMed Web of Science ®Google Scholar
• Maertens J, Frere P, Lass-Flörl C et al. Primary antifungal prophylaxis in leukaemia patients. Eur. J. Cancer Suppl.5, 43–48 (2007).
   Google Scholar
• Marchetti O, Cordonnier C, Calandra T. Empirical antifungal therapy in neutropenic cancer patients with persistent fever. Eur. J. Cancer Suppl.5, 32–42 (2007).
   Google Scholar
• Herbrecht R, Flückiger U, Gachot B et al. Treatment of invasive candida and invasive aspergillus infections in adult haematological patients. Eur. J. Cancer5(2), 49–59 (2007).
   Google Scholar
• Maertens J, Marchetti O, Herbrecht R et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL3 – 2009 update. Bone Marrow Transplant. DOI: 10.1038/bmt.2010.175 (2010) (Epub ahead of print).
   Google Scholar
• Walsh TJ, Anaissie EJ, Dennin DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis.46, 327–360 (2008).
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis.48, 503–535 (2009).
   PubMed Web of Science ®Google Scholar
• Cornely OA, Böhme A, Buchheidt D et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica94, 113–122 (2009).
   PubMed Web of Science ®Google Scholar
• Böhme A, Rünhke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients – recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann. Hematol.88, 97–110 (2009).
   PubMed Web of Science ®Google Scholar
• Girmenia C, Barosi G, Aversa F et al. Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Clin. Infect. Dis.49, 1226–1236 (2009).
   PubMed Web of Science ®Google Scholar
• Marr KA, Bow E, Chiller T et al. Fungal infection prevention after hematopoeitic cell transplantation. Bone Marrow Transplant.44, 483–487 (2009).
   PubMed Web of Science ®Google Scholar
• Tomblyn M, Chiller T, Einsele H et al. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. Biology Bone Marrow Transplant.15, 1143–1238 (2009).
   PubMed Web of Science ®Google Scholar
• Tomblyn M, Chiller T, Einsele H et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective: preface. Bone Marrow Transplant.44, 453–455 (2009).
   PubMed Web of Science ®Google Scholar
• Segal BH, Freifeld AG, Baden LR et al. Prevention and treatment of cancer-related infections. J. Natl Compr. Canc. Netw.6, 122–174 (2008).
   PubMedGoogle Scholar
• Slavin MA, Szer J, Roberts AW et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern. Med. J.34, 192–200 (2004).
   PubMed Web of Science ®Google Scholar
• Gavalda J, Ruiz I. Guidelines for the treatment of infection due to Aspergillus spp. Enferm. Infecc. Microbiol. Clin.21, 571–578 (2004).
   Google Scholar
• Denning DW, Kibbler C, Barnes RA. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect. Dis.3, 230–240 (2003).
   PubMed Web of Science ®Google Scholar
• Kish MA. Guide to development of practice guidelines. Clin. Infect. Dis.32, 851–854 (2001).
   PubMed Web of Science ®Google Scholar
• Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood103, 1527–1533 (2004).
   PubMed Web of Science ®Google Scholar
• Winston DJ, Hathorn JW, Schuster MG et al. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am. J. Med.108, 282–289 (2000).
   PubMed Web of Science ®Google Scholar
• Van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis.39, 1407–1416 (2004).
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med.356, 335–347 (2007).
   PubMed Web of Science ®Google Scholar
• Rijnders BJ, Cornelissen JJ, Slobbe L et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin. Infect. Dis.46, 1401–1408 (2008).
   PubMed Web of Science ®Google Scholar
• Marks DI, Kibbler C, Pagliugi A et al. Voriconazole (VOR) vs itraconazole (ITR) for primary prophylaxis of invasive fungal infection (IFI) in allogeneic hematopoietic cell transplant (HCT) recipient. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12–15 September 2009.
   Google Scholar
• Wingard JR, Carter SL, Walsh TJ et al. Results of a randomized, double-blind trial of fluconazole vs. voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients. Blood110, 55A (2007) (Abstract 163).
   Web of Science ®Google Scholar
• Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood96, 2055–2061 (2000).
   PubMed Web of Science ®Google Scholar
• Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann. Intern. Med.138, 705–713 (2003).
   PubMed Web of Science ®Google Scholar
• Rotstein C, Bow E, Laverdiere M et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin. Infect. Dis.28, 331–340 (1999).
   PubMed Web of Science ®Google Scholar
• Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J. Infect. Dis.172, 1035–1041 (1995).
   PubMed Web of Science ®Google Scholar
• Winston DJC, Chandrasekar PH, Lazarus HM et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind multicenter trial. Ann. Intern. Med.188, 495–503 (1993).
   Google Scholar
• Glasmacher A, Prentice A, Gorschlüter M et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J. Clin. Oncol.15, 4615–4626 (2003).
   Google Scholar
• Glasmacher A, Molitor E, Han C et al. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia12, 1338–1343 (1998).
   PubMed Web of Science ®Google Scholar
• Mattiuzi GN, Cortes J, Alvarado G et al. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support. Care Cancer DOI: 10.1007/s00520-009-0783-3 (2009) (Epub ahead of print).
   Google Scholar
• Mattiuzi GN, Alvarado G, Giles FJ et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob. Agents Chemother.50, 143–147 (2006).
   PubMedGoogle Scholar
• Tollemar J, Ringden O, Andersson S et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant.12, 577–582 (1993).
   PubMed Web of Science ®Google Scholar
• Kelsey SM, Goldman JM, McCann S et al. Liposomal amphotericin (Ambisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant.23, 163–168 (1999).
   PubMed Web of Science ®Google Scholar
• Penack O, Schwartz S, Martus P et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center study. Ann. Oncol.17, 1306–1312 (2006).
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Mohty M, Faucher C et al. Safety of a weekly high dose of liposomal amhptericin B for prophylaxis of invasive fungal infection in immunocompromised patients: prophysome study. Int. J. Antimicrob. Agents31, 135–141 (2008).
   PubMed Web of Science ®Google Scholar
• De Fabritiis P, Spagnoli A, Di Bartolomeo P et al. Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with pulmonary and/or systemic fungal infection. Bone Marrow Transplant.40, 245–249 (2007).
   PubMed Web of Science ®Google Scholar
• Fukuda T, Boeckh M, Guthrie K et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10 year experience at a single transplant center. Biol. Bone Marrow Transplant.10, 494–503 (2004).
   PubMed Web of Science ®Google Scholar
• Kruger WH, Russmann B, de Wit M et al. Haematopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematologica113, 104–108 (2005).
   PubMed Web of Science ®Google Scholar
• Martino R, Parody R, Maertens J et al. Impact of the intensity of the pretransplant conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood108, 2928–2936 (2006).
   PubMed Web of Science ®Google Scholar
• Cornely OA, Böhme A, Reichert S et al. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J. Antimicrob. Chemother.61, 939–946 (2008).
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Einsele H, Rovira M et al. Voriconazole for secondary prophylaxis of invasive fungal infection in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica DOI: 10.3324/haematol.2009.020073 (2010) (Epub ahead of print).
   Google Scholar
• EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am. J. Med.86, 668–672 (1989).
   PubMed Web of Science ®Google Scholar
• Pizzo P, Robichaud KJ, Gill FA et al. Empirical antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am. J. Med.72, 101–111 (1982).
   PubMed Web of Science ®Google Scholar
• Boogaerts M, Winston DJ, Bow E et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. Ann. Intern. Med.135, 412–422 (2001).
   PubMed Web of Science ®Google Scholar
• Viscoli C, Castagnola E, Van Lint MT et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised trial. Eur. J. Cancer32A, 814–820 (1996).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N. Engl. J. Med.340, 764–771 (1999).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med.346, 225–234 (2002).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med.351, 1391–1402 (2004).
   PubMed Web of Science ®Google Scholar
• Wingard JR, White MH, Anaissie E et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin. Infect. Dis.31, 1155–1163 (2000).
   PubMed Web of Science ®Google Scholar
• Cornely O, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis.44, 1289–1297 (2007).
   PubMed Web of Science ®Google Scholar
• Maertens J, Theunissen K, Verhoef G et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin. Infect. Dis.41, 1242–1250 (2005).
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Pautas C, Maury S et al. Empirical versus pre-emptive antifungal strategy in high-risk febrile neutropenic patients: a prospective randomized study. Clin. Infect. Dis.48, 1042–1051 (2009).
   PubMed Web of Science ®Google Scholar
• Hebart H, Klingspor L, Klingebiel T et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after Allo-SCT. Bone Marrow Transplant.43, 553–561 (2008).
   PubMedGoogle Scholar
• Aguilar-Guisado M, Espigado I, Cordero E et al. Empirical antifungal therapy in selected patients with persistent febrile neutropenia. Bone Marrow Transplant.45, 159–164 (2010).
   PubMedGoogle Scholar
• Barnes RA, White PL, Bygrave C et al. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J. Clin. Pathol.62, 64–69 (2009).
   PubMed Web of Science ®Google Scholar
• Dignan FL, Evans SO, Ethell ME et al. An early CT-diagnosis based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. Bone Marrow Transplant.44, 51–56 (2009).
   PubMed Web of Science ®Google Scholar
• Girmenia C, Micozzi A, Gentile G et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J. Clin. Oncol.28, 667–674 (2010).
   PubMed Web of Science ®Google Scholar
• Riva E, Nosari A, Brizio A et al. In high risk acute leukemia patients, early antifungal therapy improve the outcome of invasive mould infections. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September 2007.
   Google Scholar
• Maschmeyer G, Beinert T, Buchheidt D et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur. J. Cancer45, 2462–2472 (2009).
   PubMedGoogle Scholar
• Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med.347, 2020–2029 (2002).
   PubMed Web of Science ®Google Scholar
• Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a Phase III randomised double-blind trial. Lancet369, 1519–1527 (2007).
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med.356, 2472–2482 (2007).
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis.45, 883–893 (2007).
   PubMed Web of Science ®Google Scholar
• Betts RF, Nucci M, Talwar D et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin. Infect. Dis.48, 1676–1684 (2009).
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Benjamin DK, Kontoyiannis DP et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin. Infect. Dis.39, 192–198 (2004).
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Maertens J, Baila L et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant.45, 1227–1233 (2010).
   PubMed Web of Science ®Google Scholar
• Viscoli C, Herbrecht R, Akan H et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J. Antimicrob. Chemother.64, 1274–1281 (2009).
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Pettrikos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis.39, 1563–1571 (2004).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis.44, 2–12 (2007).
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis.34, 563–571 (2002).
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Bresnik M, Ebrahimi R. Liposomal Amphotericin B (AmBisome®). efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis. Mycoses50, 205–209 (2007).
   PubMedGoogle Scholar
• Pascual A, Calandra T, Bolay S et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis.46, 201–211 (2008).
   PubMed Web of Science ®Google Scholar
• Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother.50, 1570–1572 (2006).
   PubMed Web of Science ®Google Scholar
• Tan K, Brayshaw N, Tomasweski K et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse effects or liver function tests abnormalities. Clin. Pharmacol.46, 235–243 (2006).
   Google Scholar
• Horn D, Neofytos D, Fishman J et al. Use of the PATH alliance data base to measure adherence to IDSA guidelines for the therapy of candidemia. Eur. J. Clin. Microbiol. Infect.26, 907–914 (2007).
   PubMed Web of Science ®Google Scholar
• Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Clin. Infect. Dis.30, 662–678 (2000).
   PubMed Web of Science ®Google Scholar
• Patel M, Kunz DF, Trivedi VM et al. Initial management of candidemia at an academic medical center: evaluation of the IDSA guidelines. Diagn. Microbiol. Infect. Dis.52, 29–34 (2005).
   PubMed Web of Science ®Google Scholar